Interleukin (IL)‐23p19 and IL‐17 inhibitors have demonstrated high efficacy for psoriasis in randomized controlled trials, though real‐world data, particularly for risankizumab (IL‐23p19 inhibitor) and brodalumab (IL‐17 receptor (IL‐17R) inhibitor), is limited. This evidence concerns the gene IL23A and psoriasis.